E
Everest Medicines Ltd
HKEX:1952
Everest Medicines Ltd
HKEX:1952
Price:
32.54
HKD
-1.45%
Market Closed
Market Cap:
HK$11.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
E
|
Everest Medicines Ltd
HKEX:1952
|
CN |
|
Macrotech Developers Ltd
BSE:543287
|
IN |
|
X
|
Xiamen R&T Plumbing Technology Co Ltd
SZSE:002790
|
CN |
|
Mitsubishi Heavy Industries Ltd
TSE:7011
|
JP |
|
Ningbo Exciton Technology Co Ltd
SZSE:300566
|
CN |
|
N
|
Nur Ink Innovations Ltd
TASE:NURI
|
IL |
|
Barry Callebaut AG
SIX:BARN
|
CH |
|
Jizhong Energy Resources Co Ltd
SZSE:000937
|
CN |
|
TAG Oil Ltd
XTSX:TAO
|
CA |
|
J
|
JK Tyre & Industries Ltd
NSE:JKTYRE
|
IN |
|
Anteotech Ltd
ASX:ADO
|
AU |
|
Digital China Information Service Co Ltd
SZSE:000555
|
CN |
|
W
|
Wong's Kong King International (Holdings) Ltd
HKEX:532
|
HK |
Relative Value
The Relative Value of one Everest Medicines Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 32.54 HKD, Everest Medicines Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Everest Medicines Ltd Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Everest Medicines Ltd Competitors
Everest Medicines Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
E
|
Everest Medicines Ltd
HKEX:1952
|
10.4B HKD | 10.8 | -13.9 | -13.3 | -10.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.3B USD | 5.9 | 86.8 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.2 | 24.6 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.4B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD | 9.5 | 28.9 | 21.7 | 22.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD | 3.1 | 34.2 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.1 | 32.5 | 35.1 | 35.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
